Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 plus gemcitabine for first-line metastatic pancreatic cancer
jRCT2080221160Phase 1
- Sponsor
- Takeda
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganitumab in pancreatic adenocarcinoma (PDAC), sponsored by Takeda.
02
Drugs
ganitumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2080221160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221160.